HOLX 📈 Hologic - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4364401012
HOLX: Diagnostic Tests, Medical Imaging Systems, Surgical Instruments
Hologic, Inc. is a healthcare company that specializes in developing, manufacturing, and supplying a wide range of medical products, with a primary focus on women's health. The company's product portfolio is diverse, encompassing diagnostics, medical imaging systems, and surgical products, all designed to facilitate early detection and treatment of various health issues. Hologic operates through four distinct segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health, each catering to specific aspects of women's health.
The Diagnostics segment offers a variety of molecular diagnostic assays, including the Aptima line, which is used to detect infectious microorganisms such as Hepatitis B and C, HIV, and human cytomegalovirus. Additionally, the company provides assays for diagnosing vaginitis, as well as tests for detecting SARS-CoV-2. The ThinPrep System is another key product, used for cytology applications, while the Rapid Fetal Fibronectin Test helps physicians assess the risk of pre-term birth. These products are designed to provide accurate and reliable diagnostic results, enabling healthcare professionals to make informed decisions about patient care.
In the area of breast health, Hologic offers a comprehensive range of solutions, including 3D digital mammography systems, image analytics software, and minimally invasive breast biopsy guidance systems. The company's breast cancer care products are designed to support radiology, breast surgery, pathology, and treatment, with the goal of improving patient outcomes. For example, the company's breast biopsy site markers and localization products help guide surgeons during procedures, while its specimen radiology and connectivity solutions facilitate the sharing of medical images and information.
The GYN Surgical segment offers a range of products for the treatment of uterine health issues, including the MyoSure Hysteroscopic Tissue Removal System, which is used to remove fibroids and polyps. The NovaSure Endometrial Ablation System is another key product, designed to treat abnormal uterine bleeding. The Fluent Fluid Management System provides liquid distention during diagnostic and operative hysteroscopic procedures, while the Acessa ProVu system is used to treat various types of fibroids. The CoolSeal portfolio, which includes bipolar vessel sealing devices, is also part of the company's GYN Surgical product line.
In addition to its women's health products, Hologic also offers a range of skeletal health solutions, including the Horizon DXA, a dual energy X-ray system used to assess bone density. The Fluoroscan Insight FD mini C-arm is another key product, used to perform minimally invasive orthopedic surgical procedures. The company's products are sold through a variety of channels, including direct sales, service forces, independent distributors, and sales representatives, allowing it to reach a wide range of customers and healthcare providers.
Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts. With a strong focus on innovation and customer satisfaction, the company has established itself as a leading provider of medical products and solutions for women's health and skeletal health. Its commitment to delivering high-quality products and services has earned it a reputation as a trusted partner in the healthcare industry. For more information, please visit the company's website at https://www.hologic.com. The company's common stock is listed on the NASDAQ stock exchange under the ticker symbol HOLX, and its ISIN is US4364401012, with a GICS Sub Industry classification of Health Care Equipment.
Additional Sources for HOLX Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HOLX Stock Overview
Market Cap in USD | 18,042m |
Sector | Healthcare |
Industry | Medical Instruments & Supplies |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 1990-06-21 |
HOLX Stock Ratings
Growth 5y | 42.3% |
Fundamental | 70.7% |
Dividend | - |
Rel. Strength Industry | -63.2 |
Analysts | 3.74/5 |
Fair Price Momentum | 62.66 USD |
Fair Price DCF | 130.53 USD |
HOLX Dividends
No Dividends PaidHOLX Growth Ratios
Growth Correlation 3m | -78.8% |
Growth Correlation 12m | 60.2% |
Growth Correlation 5y | 61.2% |
CAGR 5y | 6.38% |
CAGR/Mean DD 5y | 0.53 |
Sharpe Ratio 12m | -0.12 |
Alpha | -22.38 |
Beta | 0.87 |
Volatility | 21.41% |
Current Volume | 8613.8k |
Average Volume 20d | 2608.8k |
As of December 21, 2024, the stock is trading at USD 71.65 with a total of 8,613,766 shares traded.
Over the past week, the price has changed by -2.72%, over one month by -8.19%, over three months by -11.97% and over the past year by +1.89%.
Yes, based on ValueRay Fundamental Analyses, Hologic (NASDAQ:HOLX) is currently (December 2024) a good stock to buy. It has a ValueRay Fundamental Rating of 70.71 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HOLX as of December 2024 is 62.66. This means that HOLX is currently overvalued and has a potential downside of -12.55%.
Hologic has received a consensus analysts rating of 3.74. Therefor, it is recommend to hold HOLX.
- Strong Buy: 5
- Buy: 5
- Hold: 8
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, HOLX Hologic will be worth about 68.9 in December 2025. The stock is currently trading at 71.65. This means that the stock has a potential downside of -3.81%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 87.2 | 21.7% |
Analysts Target Price | 86.6 | 20.9% |
ValueRay Target Price | 68.9 | -3.8% |